- Home
- CSTL vs HZO Comparison
CSTL vs HZO Comparison
Compare CSTL & HZO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CSTL
- HZO
- Stock Information
- Founded
- CSTL 2007
- HZO 1998
- Country
- CSTL United States
- HZO United States
- Employees
- CSTL N/A
- HZO N/A
- Industry
- CSTL Medical Specialities
- HZO Auto & Home Supply Stores
- Sector
- CSTL Health Care
- HZO Consumer Discretionary
- Exchange
- CSTL Nasdaq
- HZO Nasdaq
- Market Cap
- CSTL 697.9M
- HZO 604.0M
- IPO Year
- CSTL 2019
- HZO 1998
- Fundamental
- Price
- CSTL $22.75
- HZO $25.72
- Analyst Decision
- CSTL Strong Buy
- HZO Strong Buy
- Analyst Count
- CSTL 6
- HZO 4
- Target Price
- CSTL $37.67
- HZO $33.25
- AVG Volume (30 Days)
- CSTL 348.6K
- HZO 402.8K
- Earning Date
- CSTL 11-03-2025
- HZO 10-30-2025
- Dividend Yield
- CSTL N/A
- HZO N/A
- EPS Growth
- CSTL N/A
- HZO N/A
- EPS
- CSTL N/A
- HZO N/A
- Revenue
- CSTL $346,269,000.00
- HZO $2,320,257,000.00
- Revenue This Year
- CSTL N/A
- HZO N/A
- Revenue Next Year
- CSTL N/A
- HZO $3.85
- P/E Ratio
- CSTL N/A
- HZO N/A
- Revenue Growth
- CSTL 20.40
- HZO N/A
- 52 Week Low
- CSTL $14.59
- HZO $16.85
- 52 Week High
- CSTL $35.84
- HZO $35.46
- Technical
- Relative Strength Index (RSI)
- CSTL 52.78
- HZO 47.36
- Support Level
- CSTL $22.28
- HZO $24.84
- Resistance Level
- CSTL $23.71
- HZO $28.29
- Average True Range (ATR)
- CSTL 1.05
- HZO 1.13
- MACD
- CSTL -0.12
- HZO -0.02
- Stochastic Oscillator
- CSTL 35.90
- HZO 16.81
About CSTL Castle Biosciences Inc.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.
About HZO MarineMax Inc. (FL)
MarineMax Inc is a United-States-based company that sells new and used recreational boats under premium brands, and related marine products, like engines, parts, and accessories. The company is also engaged in other businesses, including providing services of repair, maintenance, and storage; managing related boat financing, insurance, and others; offering brokerage sales of boats and yachts; and operating a yacht charter business. The reportable segments of the company are Retail Operations and Product Manufacturing. The Retail Operations segment generates the majority of the company's revenue. The sale of new and used boats accounts for the majority of the company's total revenue. It serves customers across the U.S.